Trajan Wealth LLC raised its position in shares of IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 8.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 162,157 shares of the medical research company’s stock after acquiring an additional 12,616 shares during the quarter. IQVIA makes up about 1.5% of Trajan Wealth LLC’s holdings, making the stock its 16th largest holding. Trajan Wealth LLC’s holdings in IQVIA were worth $36,552,000 at the end of the most recent reporting period.
A number of other hedge funds have also made changes to their positions in the company. Claret Asset Management Corp raised its holdings in shares of IQVIA by 1.1% during the third quarter. Claret Asset Management Corp now owns 4,527 shares of the medical research company’s stock valued at $860,000 after acquiring an additional 49 shares during the last quarter. Leonard Rickey Investment Advisors P.L.L.C. grew its position in shares of IQVIA by 3.3% in the fourth quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 1,814 shares of the medical research company’s stock valued at $409,000 after purchasing an additional 58 shares in the last quarter. Brookstone Capital Management grew its position in shares of IQVIA by 2.2% in the fourth quarter. Brookstone Capital Management now owns 2,931 shares of the medical research company’s stock valued at $661,000 after purchasing an additional 63 shares in the last quarter. Private Advisor Group LLC grew its position in shares of IQVIA by 1.0% in the third quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock valued at $1,163,000 after purchasing an additional 63 shares in the last quarter. Finally, Keybank National Association OH grew its position in shares of IQVIA by 0.7% in the fourth quarter. Keybank National Association OH now owns 9,103 shares of the medical research company’s stock valued at $2,052,000 after purchasing an additional 67 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.
IQVIA Stock Down 1.0%
IQV opened at $171.47 on Thursday. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $247.04. The business’s 50-day simple moving average is $169.85 and its 200-day simple moving average is $198.11. The stock has a market capitalization of $28.62 billion, a P/E ratio of 21.25, a price-to-earnings-growth ratio of 1.66 and a beta of 1.18.
IQVIA declared that its Board of Directors has authorized a stock buyback plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board believes its stock is undervalued.
Analysts Set New Price Targets
Several brokerages recently weighed in on IQV. Evercore reiterated an “outperform” rating and issued a $185.00 price objective on shares of IQVIA in a research report on Wednesday, April 8th. Stifel Nicolaus lowered their price objective on IQVIA from $273.00 to $220.00 and set a “buy” rating for the company in a research report on Friday, February 6th. Citigroup lowered their price objective on IQVIA from $230.00 to $200.00 and set a “neutral” rating for the company in a research report on Friday, February 6th. Royal Bank Of Canada began coverage on IQVIA in a research report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price target for the company. Finally, Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a research report on Sunday, April 19th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $225.69.
Read Our Latest Research Report on IQV
About IQVIA
IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.
IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.
See Also
- Five stocks we like better than IQVIA
- The Palantir Paradox—Record Numbers and a Stock That Won’t Cooperate
- TJX Companies Fires on All Cylinders With 9% Revenue Growth
- From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
- AI Consolidation Begins: Blackstone & Google Forge an AI Empire
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
